Business
Formation of Healthcare Investment Committee
Formation of Healthcare Investment Committee.
About this update from Duke Capital Limited
[{"type":"text","content":"\n \nRNS Number : 4294Z Duke Royalty Limited 17 September 2015 \n\n17 September 2015\nDuke Royalty Limited\n(\"Duke Royalty\" or the \"Company\")\n \nDuke Royalty announces the formation of its Healthcare Investment Committee \n \nAs previously reported Duke Royalty Limited, a public diversified royalty company (AIM: DUKE), and Oliver Wyman, a management consultancy wholly owned by Marsh & McLennan Companies (NYSE: MMC), have created a unique financing collaboration in the rapidly developing pharmaceutical and healthcare-related royalty market.\nWithin the framework of that collaboration, Duke is pleased to announce that it has now appointed a specialised investment committee who will assist the Company in analysing and recommending potential healthcare royalty transactions. Collectively, the committee members have advised on over US$ 2 billion of healthcare royalty transactions and have over one hundred years combined experience. The investment committee's responsibilities will include:\n· reviewing the pipeline of proposed healthcare and pharmaceutical investment opportunities including deals proposed by Oliver Wyman;\n· assisting and advising on royalty investment terms;\n· identifying and managing potential conflicts of interests;\n· assessing the individual capital requirements for each potential opportunity and;\n· reviewing the performance and outlook of the investment portfolio \nThe Investment Committee will have access to all due diligence material in connection with any proposed investments. Once it has analysed the merits of a particular transaction, it will provide an investment recommendation to the board of Duke Royalty with all final investment decisions being made by the Company's Board in Guernsey.\nThe composition of the investment committee will be made up of a mix of Duke Royalty, Oliver Wyman and independent representatives. These individuals have a blend of deep healthcare experience from the fields of advisory, royalty and principal investing.\nAlong with Neil Johnson, the Company's Chief Executive Officer, the investment committee will include:\nJim Webster\nMr Webster pioneered the institutional approach to investing in pharmaceutical and biotech royalties for...